These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 16956440)

  • 1. Efficacy of infliximab in long-lasting refractory Kawasaki disease.
    Zulian F; Zanon G; Martini G; Mescoli G; Milanesi O
    Clin Exp Rheumatol; 2006; 24(4):453. PubMed ID: 16956440
    [No Abstract]   [Full Text] [Related]  

  • 2. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.
    Tremoulet AH; Jain S; Jaggi P; Jimenez-Fernandez S; Pancheri JM; Sun X; Kanegaye JT; Kovalchin JP; Printz BF; Ramilo O; Burns JC
    Lancet; 2014 May; 383(9930):1731-8. PubMed ID: 24572997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study.
    Son MB; Gauvreau K; Burns JC; Corinaldesi E; Tremoulet AH; Watson VE; Baker A; Fulton DR; Sundel RP; Newburger JW
    J Pediatr; 2011 Apr; 158(4):644-649.e1. PubMed ID: 21129756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infliximab treatment for pediatric refractory Kawasaki disease.
    Blaisdell LL; Hayman JA; Moran AM
    Pediatr Cardiol; 2011 Oct; 32(7):1023-7. PubMed ID: 21773835
    [No Abstract]   [Full Text] [Related]  

  • 5. Infliximab treatment in refractory Kawasaki syndrome.
    Girish M; Subramaniam G
    Indian J Pediatr; 2008 May; 75(5):521-2. PubMed ID: 18537019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Refractory Kawasaki disease: infliximab or methotrexate therapy?
    Shin JI; Lee JS; Choi JY; Kim DS; Girish M; Subramaniam
    Indian J Pediatr; 2009 Nov; 76(11):1184; author reply 1184. PubMed ID: 20072867
    [No Abstract]   [Full Text] [Related]  

  • 7. Infliximab as a novel therapy for refractory Kawasaki disease.
    Weiss JE; Eberhard BA; Chowdhury D; Gottlieb BS
    J Rheumatol; 2004 Apr; 31(4):808-10. PubMed ID: 15088313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab treatment for refractory Kawasaki syndrome.
    Burns JC; Mason WH; Hauger SB; Janai H; Bastian JF; Wohrley JD; Balfour I; Shen CA; Michel ED; Shulman ST; Melish ME
    J Pediatr; 2005 May; 146(5):662-7. PubMed ID: 15870671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should infliximab be used as an adjuvant to IVIG in the treatment of children with Kawasaki disease who are at high risk for resistance to conventional therapy?
    Davies S; Gold-von Simson G
    Pediatr Cardiol; 2013 Oct; 34(7):1756. PubMed ID: 23771701
    [No Abstract]   [Full Text] [Related]  

  • 10. Incomplete and atypical Kawasaki disease in a young infant: severe, recalcitrant disease responsive to infliximab.
    O'connor MJ; Saulsbury FT
    Clin Pediatr (Phila); 2007 May; 46(4):345-8. PubMed ID: 17475994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of TNFalpha blockade in complicated, refractory Kawasaki disease.
    Stenbøg EV; Windelborg B; Hørlyck A; Herlin T
    Scand J Rheumatol; 2006; 35(4):318-21. PubMed ID: 16882598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Refractory Kawasaki disease with coronary aneurysms treated with infliximab].
    Salguero JS; Durán DG; Peracaula CS; Iznardi CR; Tardío JO
    An Pediatr (Barc); 2010 Nov; 73(5):268-71. PubMed ID: 20678974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infliximab for Kawasaki syndrome.
    Saji T; Kemmotsu Y
    J Pediatr; 2006 Sep; 149(3):426; author reply 426. PubMed ID: 16939768
    [No Abstract]   [Full Text] [Related]  

  • 14. [Kawasaki disease: what you need to know].
    Bajolle F; Laux D
    Arch Pediatr; 2012 Nov; 19(11):1264-8. PubMed ID: 22921712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infliximab for the treatment of Kawasaki disease.
    Matsubara T
    Pediatr Int; 2018 Sep; 60(9):775. PubMed ID: 30255976
    [No Abstract]   [Full Text] [Related]  

  • 16. [Anti TNF-α (infliximab) treatment for intravenous immunoglobulin (IVIG) resistance patients with acute Kawasaki disease the effects of anticytokine therapy].
    Saji T; Takatsuki S; Kobayashi T
    Nihon Rinsho; 2014 Sep; 72(9):1641-9. PubMed ID: 25518416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab treatment for refractory Kawasaki disease with coronary artery aneurysm.
    Oishi T; Fujieda M; Shiraishi T; Ono M; Inoue K; Takahashi A; Ogura H; Wakiguchi H
    Circ J; 2008 May; 72(5):850-2. PubMed ID: 18441471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of severe complicated Kawasaki disease with oral prednisolone and aspirin.
    Dale RC; Saleem MA; Daw S; Dillon MJ
    J Pediatr; 2000 Nov; 137(5):723-6. PubMed ID: 11060542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infliximab administration effective in the treatment of refractory Kawasaki disease.
    Accomando S; Liotta A; Maggio MC; Cardella F; Corsello G
    Pediatr Allergy Immunol; 2010 Nov; 21(7):1091-2. PubMed ID: 20977502
    [No Abstract]   [Full Text] [Related]  

  • 20. Infliximab reduces the cytokine-mediated inflammation but does not suppress cellular infiltration of the vessel wall in refractory Kawasaki disease.
    Hirono K; Kemmotsu Y; Wittkowski H; Foell D; Saito K; Ibuki K; Watanabe K; Watanabe S; Uese K; Kanegane H; Origasa H; Ichida F; Roth J; Miyawaki T; Saji T
    Pediatr Res; 2009 Jun; 65(6):696-701. PubMed ID: 19430379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.